




Fluid
therapy.org

Chapter 25:

Hypercalcemia



To get a copy of the book, visit: www.fluidtherapy.org

Table of Contents

Part 1 Physiology

Overview of total body fluid distribution, water balance, and electrolyte compartments.

Chapter 1

Part 2 Basics of Intravenous Fluids and Solutions

Introduction to crystalloids and colloids, their composition, clinical use, precautions, and contraindications.

Chapter 2-5

Part 3 Fluid Replacement Strategies

Principles of fluid therapy, including maintenance, resuscitation, and special considerations for the elderly.

Chapter 6-9

Part 4 Parenteral Additives

Composition, clinical applications, and precautions for various parenteral additives.

Chapter 10-14

Part 5 Hemodynamic Monitoring

Principles and techniques for assessing fluid status and cardiac output, using basic and advanced methods.

Chapter 15-19

Part 6 Electrolyte Disorders

Causes, presentation, diagnosis, and management of various electrolyte imbalances.

Chapter 20-29

Part 7 Acid-Base Disorders

Concepts, interpretation, and management of metabolic and respiratory acid-base disorders.

Chapter 30-33

Part 8 Fluid Therapy in Medical Disorders

Guidelines for fluid management in conditions like GI diseases, liver disorders, respiratory issues, and diabetic emergencies.

Chapter 34-41

Part 9 Fluid Therapy in Surgical Disorders

Fluid management before, during, and after surgery, including TURP syndrome and burns.

Chapter 42-47

Part 10 Fluid Therapy in Pediatrics

Special considerations for fluid management in children and neonates, including resuscitation, maintenance, and oral rehydration.

Chapter 48-50

Part 11 Fluid Therapy in Obstetrics

Fluid management strategies for pregnancy, cesarean delivery, preeclampsia, and labor-related hyponatremia.

Chapter 51-54

Part 12 Parenteral Nutrition

Principles, indications, and administration of parenteral nutrition, with disease-specific guidelines and complication management.

Chapter 55-57

25

Hypercalcemia

Etiology	299	Selection of modality	305
Primary hyperparathyroidism	299	To increase urinary excretion	305
Malignancy	300	Isotonic saline hydration.....	305
Vitamin D toxicity.....	300	Furosemide	307
Milk alkali syndrome	301	To inhibit bone resorption	307
Granulomatous diseases.....	301	Calcitonin.....	307
Thiazide diuretics	301	Bisphosphonates.....	307
Immobilization	301	Denosumab	308
Clinical Features.....	301	To decrease intestinal absorption..	308
Diagnosis	302	Glucocorticoids.....	308
Confirm the diagnosis.....	302	Phosphate	308
History and physical examination..	302	To remove calcium directly	308
Measure serum PTH	303	Dialysis.....	308
Order other tests	304	Specific treatment of underlying causes	309
Management.....	305		

Hypercalcemia is a less common disorder than hypocalcemia, occurring in about 0.6–7.5% of hospitalized and less than 1.0% of outpatients [1–6].

Hypercalcemia is defined as total serum calcium >10.5 mg/dL (>2.6 mmol/L) with normal serum albumin or ionized calcium >5.2 mg/dL (>1.3 mmol/L) [7].

When total serum calcium is >14.0 mg/dL (>3.5 mmol/L) or ionized calcium is >7.0 mg/dL (>1.7 mmol/L), it is considered severe hypercalcemia [7]. Early detection and prompt treatment of hypercalcemia are essential because

it carries high morbidity and mortality [7, 8].

ETIOLOGY

Primary hyperparathyroidism and malignancy are the two most common causes of hypercalcemia in more than 90% of patients [7, 9]. In recent times, there has been a significant rise in hypercalcemia due to Vitamin D toxicity.

Mechanisms by which different etiologies cause hypercalcemia are enhanced bone resorption, increased intestinal absorption, or decreased renal calcium excretion (Table 25.1).

Want to read more?

[Get Printed Version](#)[Get Kindle Version](#)

REFERENCES

1. Fiskin RA, Heath DA, Somers S, et al. Hypercalcemia in hospital patients: clinical and diagnostic aspects. *Lancet*. 1981;1(8213):202–7.
2. Dent DM, Miller JL, Klaff L, et al. The incidence and causes of hypercalcemia. *Postgrad Med J*. 1987;63(743):745–750.
3. Lee CT, Yang CC, Lam KK, et al. Hypercalcemia in the emergency department. *Am J Med Sci*. 2006;331(3):119–23.
4. Lindner G, Felber R, Schwarz C, et al. Hypercalcemia in the ED: prevalence, etiology, and outcome. *Am J Emerg Med*. 2013;31(4):657–60.
5. Catalano A, Chilà D, Bellone F, et al. Incidence of hypocalcemia and hypercalcemia in hospitalized patients: Is it changing? *J Clin Transl Endocrinol*. 2018;13:9–13.
6. Korkut S, Polat Ö, Kazancı MH, et al. Hypercalcemia in the emergency department: prevalence, etiology, and mortality rate. *Med J Bakirkoy* 2020;16(2):143–7.
7. Carroll MF, Schade DS. A practical approach to hypercalcemia. *Am Fam Physician*. 2003;67(9):1959–66.
8. Mousseaux C, Dupont A, Rafat C, et al. Epidemiology, clinical features, and management of severe hypercalcemia in critically ill patients. *Ann Intensive Care*. 2019;9(1):133.
9. Renaghan ADM, Rosner M. Hypercalcemia: etiology and management. *Nephrol Dial Transpl*. 2018;33(6):549–551.
10. Khoury N, Carmichael KA. Evaluation and therapy of hypercalcemia. *Mo Med*. 2011;108(2):99–103.
11. Bilezikian JP. Primary Hyperparathyroidism. *J Clin Endocrinol Metab*. 2018;103(11):3993–4004.
12. Afzal M, Kathuria P. Familial Hypocalciuric Hypercalcemia. [Updated 2021 Jul 23]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK459190/>.
13. Marx SJ. Familial Hypocalciuric Hypercalcemia as an Atypical Form of Primary Hyperparathyroidism. *J Bone Miner Res*. 2018;33(1):27–31.
14. Lafferty FW. Differential diagnosis of hypercalcemia. *J Bone Miner Res* 1991;6(Suppl 2):S51–S59.
15. Stewart AF. Clinical practice. Hypercalcemia associated with cancer. *N Engl J Med* 2005;352(4):373–379.
16. Gastanaga VM, Schwartzberg LS, Jain RK, et al. Prevalence of hypercalcemia among cancer patients in the United States. *Cancer Med* 2016;5(8):2091–100.
17. Zagzag J, Hu MI, Fisher SB, et al. Hypercalcemia and cancer: Differential diagnosis and treatment. *CA Cancer J Clin*. 2018;68(5):377–386.
18. Tebben PJ, Singh RJ, Kumar R. Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment. *Endocr Rev*. 2016;37(5):521–547.
19. Taylor PN, Davies JS. A review of the growing risk of vitamin D toxicity from inappropriate practice. *Br J Clin Pharmacol*. 2018;84(6):1121–1127.
20. Marcinowska-Suchowierska E, Kupisz-Urbańska M, Łukaszkiewicz J, et al. Vitamin D Toxicity-A Clinical Perspective. *Front Endocrinol (Lausanne)*. 2018;9:550.
21. Çağlar A, Tuğçe Çağlar H. Vitamin D intoxication due to misuse: 5-year experience. *Arch Pediatr*. 2021;28(3):222–225.
22. Nguyen T, Joe D, Shah AD. Forget the phosphorus: A case of hypervitaminosis D-induced symptomatic hypercalcemia. *Clin Nephrol Case Stud*. 2021;9:1–3.
23. Medarov BI. Milk-alkali syndrome. *Mayo Clin Proc*. 2009;84(3):261–267.
24. Patel V, Mehra D, Ramirez B, et al. Milk-Alkali Syndrome as a Cause of Hypercalcemia in a Gentleman With Acute Kidney Injury and Excessive Antacid Intake. *Cureus*. 2021;13(2):e13056.
25. Grieff M, Bushinsky DA. Diuretics and disorders of calcium homeostasis. *Semin Nephrol*. 2011;31(6):535–541.
26. Griebeler ML, Kearns AE, Ryu E, et al. Thiazide-Associated Hypercalcemia: Incidence and Association With Primary Hyperparathyroidism Over Two Decades. *J Clin Endocrinol Metab*. 2016;101(3):1166–1173.
27. Tettero JM, van Eeghen E, Kooter AJ. Extreme hypercalcemia caused by immobilisation due

-
- to acute spinal cord injury. *BMJ Case Rep.* 2021;14(6):e241386.
28. Myśliwiec J. Mnemonics for endocrinologists: hyperparathyroidism. *Endokrynologia Polska* 2012;63(6):504–505.
 29. Ma YB, Hu J, Duan YF. Acute pancreatitis connected with hypercalcemia crisis in hyperparathyroidism: A case report. *World J Clin Cases.* 2019;7(16):2367–2373.
 30. Legrand SB. Modern management of malignant hypercalcemia. *Am J Hosp Palliat Care.* 2011;28(7):515–517.
 31. Maier JD, Levine SN. Hypercalcemia in the intensive care unit: a review of pathophysiology, diagnosis, and modern therapy. *J Intensive Care Med.* 2015;30(5):235–252.
 32. Carrick AI, Costner HB. Rapid Fire: Hypercalcemia. *Emerg Med Clin North Am.* 2018;36(3):549–555.
 33. Farkas J. Hypercalcemia Internet Book of Critical Care, June 25, 2021. <https://emcrit.org/ibcc/hypercalcemia/> Accessed 20 Dec 2021.
 34. LeGrand SB, Leskuski D, Zama I. Narrative review: furosemide for hypercalcemia: an unproven yet common practice. *Ann Intern Med.* 2008;149(4):259–63.
 35. Mirrakhimov AE. Hypercalcemia of Malignancy: An Update on Pathogenesis and Management. *N Am J Med Sci.* 2015;7(11):483–493.
 36. Austin LA, Heath H III. Calcitonin: physiology and pathophysiology. *N Engl J Med.* 1981;304(5):269–278.
 37. O'Doherty DP, Bickerstaff DR, McCloskey EV, et al. A comparison of the acute effects of subcutaneous and intranasal calcitonin. *Clin Sci (Lond).* 1990;78(2):215–9.
 38. Klezlova R, Meystre C. Hypercalcemia of malignancy management. Specialist Palliative Audit and Guideline Group May 2019 Visit: http://www.wmcarses.org.uk/wp-content/uploads/SPAGG_Hypercalcaemia_Jan-2020-Final-Version.pdf Searched on 21 Dec 2021.
 39. Wang M, Cho C, Gray C, et al. Milk-alkali syndrome: a ‘quick ease’ or a ‘long-lasting problem’. *Endocrinol Diabetes Metab Case Rep.* 2020;2020:EDM20–0028.
 40. Cohen A, Shane E. Treatment of premenopausal women with low bone mineral density. *Curr Osteoporos Rep.* 2008;6(1):39–46.
 41. Miller PD. The kidney and bisphosphonates. *Bone.* 2011;49(1):77–81.
 42. Palmer S, Tillman F 3rd, Sharma P, et al. Safety of Intravenous Bisphosphonates for the Treatment of Hypercalcemia in Patients With Preexisting Renal Dysfunction. *Ann Pharmacother.* 2021;55(3):303–310.
 43. Miller PD, Jamal SA, Evenepoel P, et al. Renal safety in patients treated with bisphosphonates for osteoporosis: a review. *J Bone Miner Res.* 2013;28(10):2049–59.
 44. Hirschberg R. Renal complications from bisphosphonate treatment. *Curr Opin Support Palliat Care.* 2012;6(3):342–7.
 45. Hanley DA, Adachi JD, Bell A, et al. Denosumab: mechanism of action and clinical outcomes. *Int J Clin Pract.* 2012;66(12):1139–46.
 46. Karuppiah D, Thanabalasingham G, Shine B, et al. Refractory hypercalcemia secondary to parathyroid carcinoma: response to high-dose denosumab. *Eur J Endocrinol.* 2014;171(1):K1–5.
 47. Camus C, Charasse C, Jouannic-Montier I, et al. Calcium free hemodialysis: experience in the treatment of 33 patients with severe hypercalcemia. *Intensive Care Med.* 1996;22(2):116–21.
 48. Loh HH, Mohd Noor N. The Use of Hemodialysis in Refractory Hypercalcemia Secondary to Parathyroid Carcinoma. *Case Rep Crit Care.* 2014;2014:140906.
 49. Trabulus S, Oruc M, Ozgun E, et al. The Use of Low-Calcium Hemodialysis in the Treatment of Hypercalcemic Crisis. *Nephron.* 2018;139(4):319–331.
 50. Marouço CN, Caeiro F, da Costa BM, et al. The use of hemodialysis in hypercalcemic crisis secondary to primary hyperparathyroidism. *Port J Nephrol Hypert.* 2021;35(2):123–127.
 51. Bentata Y, Benabdellah M, Haddiya I, et al. Severe hypercalcemia requiring acute hemodialysis: A retrospective cohort study with increased incidence during the Covid-19 pandemic. *Am J Emerg Med.* 2022;51:374–377.
 52. Wilhelm SM, Wang TS, Ruan DT, et al. The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism. *JAMA Surg.* 2016;151(10):959–968.
 53. National Guideline Centre (UK). Hyperparathyroidism (primary): diagnosis, assessment and initial management. London: National Institute for Health and Care Excellence (UK); 23 May 2019 May. (NICE Guideline, No. 132.). Visit: <https://www.nice.org.uk/guidance/ng132>.

KidneyEducation



Join the Mission to Fight Kidney Diseases

Explore the world's largest multilingual website created by a global team of over 100 nephrologists.

www.KidneyEducation.com

- » Read online or download the 200-page book "Save Your Kidneys" in 40 languages—completely free.
- » This comprehensive resource offers valuable information on preventing and managing common kidney problems, tailored for kidney patients and their families.
- » It's an authentic guide, prepared by nephrologists and free from any external funding.